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ABSTRACT 
Objective: We sought to investigate the clinical significance of secondary electrocardiographic (ECG) changes in men after using escitalopram.  
Methods: This pilot observational cohort study recruited male patients taking escitalopram for at least 6 mo in Mental Hospital of Qassim. All 
patients underwent a 12-lead ECG examination. We also measured the heart rate (HR), QTc, and QRS interval. Data on all related medical conditions 
and medications were recorded.  
Results: Fifty-three men were recruited, with a mean age of 37.39±8.39 y: 34.4% and 31.1% of these patients were taking escitalopram for 
depression and anxiety, respectively. The mean dose of escitalopram was 14.35 mg. Observations showed that 20.9% of the patients taking 
escitalopram had a fast HR (>100 beats/min [bpm]), indicative of sinus tachycardia, whereas 11.4% of patients had a slow HR (<60 bpm). The mean 
QT and QTc in patients taking escitalopram were 366.62±28.69 and 398.92±16.15 ms, respectively.  
Conclusion: Low doses of escitalopram resulted in minimal clinically significant changes. Thus, patients should be monitored when doses are 
escalated further. 
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Escitalopram is the S-enantiomer of citalopram, which is available in 
strengths of 5, 10, and 20 mg, and it is prescribed for several 
psychiatric conditions, such as major depressive disorder and 
generalized anxiety disorder [1]. Escitalopram may be involved in a 
series of several drug-to-drug interactions, such as QT prolongation, 
nodal rhythm, ventricular arrhythmias, and torsade de pointes, which 
may potentiate the magnitude of its cardiotoxicity [2]. As escitalopram 
is metabolized by cytochrome enzymes, such as CYP3A4 and CYP2C19, 
variability in responses should be expected [3]. 
Although escitalopram is considered to be less cardiotoxic than 
citalopram, several studies have considered the effect of 
escitalopram on the heart, particularly in terms of QT prolongation, 
the most obvious electrocardiographic (ECG) feature of patients who 
have been treated, and particularly overdosed, with escitalopram 
[4–7]. The threshold of clinical significance of corrected QT (QTc) is 
500 millisecond (ms) or a change in the baseline of 60 ms [4]. 
Consensus has not yet been reached with regard to these 
abnormalities [8]. However, several studies have evaluated 
citalopram with regard to its cardiotoxicity [9–11]. Such studies 
have shown that citalopram may induce almost double the 
prolongation of QTc than that by escitalopram at an equivalent 
therapeutic dose. Therefore, 20 mg of citalopram and 10 mg of 
escitalopram (the equivalent therapeutic dose) may cause QT 
prolongation of 8.5 and 4.5 ms, respectively [12]. Escitalopram 
has also been repeatedly reported to prolong the QT interval, 
although the clinical significance of this effect is still under 
debate [7, 13]. Furthermore, several official agencies have 
reported the same issue. For instance, a 10-mg and a 30-mg dose 
of escitalopram would be expected to cause changes from 
baseline of 4.3 ms (confidence interval [CI]: 2.2-6.6) and 10.7 ms 
(CI: 8.6-12.8), respectively [14]. Another study reported a 
similar prolongation of 2-5 ms in cases of chronic kidney disease 
(CKD) [15]. Several other selective serotonin reuptake inhibitors 
(SSRIs) have been reported to exert a similar impact on the 
heart. Furthermore, the risk of prolongation may increase in 
patients with CKD, those aged>60 y, and with use of 
antipsychotic and tricyclic at high doses [15–17]. 
An earlier study analyzed the plasma levels of escitalopram and 
attempted to correlate these data with QTc changes. However, no 
correlation was found, and only the use of antipsychotic and tricyclic 
agents was found to be associated with QTc prolongation [17]. This 
finding may be justified by the fact that several other confounding 
variables, such as liver function, multiple genetic alleles, QT baseline, and 
the magnitude of drug-drug interactions, exert an effect. Consequently, 
the clinical sequalae of this type of prolongation may not be well 
correlated [18]. 
Consequently, there are insufficient data in existing literature to relate 
changes in QTc to the use of escitalopram and the clinical 
consequences of such changes [8]. Therefore, in the present study, we 
sought to investigate the clinical significance of ECG changes, 
particularly in QTc, in patients taking escitalopram with no known 
cardiac diseases. 
MATERIALS AND METHODS 
This pilot observational cross-sectional cohort, phase one study was 
conducted in the Mental Hospital of Qassim (ethical approval number 
20170511). It was conducted in accordance with the principles of the 
Helsinki Declaration. The sample size required for a pilot study was 
estimated to be 50 patients. The inclusion criteria were as follows: 
adult men of Saudi nationality, those prescribed escitalopram for at 
least 6 mo for any psychiatric or medical illnesses, and those who 
agreed to be part of the research and provided informed consent. We 
excluded all patients who were diagnosed with any form of cardiac 
disease, had a history of ECG changes, or those who were taking other 
medications that might cause ECG changes aside from their psychiatric 
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medications, as these may have an impact on the accuracy and validity 
of our results. 
All patients received a 12-lead ECG examination using a standard 
approach. QT (ms) intervals were measured on lead II from the 
beginning of the Q wave to the end of the T wave. All QT intervals on 
lead II were used to calculate the mean QT duration for each ECG. 
Patients’ pulse rate (PR) was taken using an auto-measure ECG strip. 
Normal heart rate ranges from 60 to 100 beats per minute; any value 
above this range was considered to represent tachycardia, whereas 
any value below this range was considered to represent bradycardia. 
The QTc was calculated automatically by the ECG reader. The QTc is 
considered a cardiac risk factor if it is recorded as>0.43 for male 
patients and 0.45 for female patients. QRS intervals were measured 
for all ECG examinations by taking the mean duration for all QRS 
intervals in lead II. A normal duration was ≤0.12 seconds; values 
higher than this normal duration were considered abnormal. 
RESULTS 
Two hundred patients who presented with a range of psychotic 
disorders were screened for eligibility. This study included only 53 
patients who met the inclusion criteria. The mean dose of 
escitalopram was 14.35 mg. All patients were men, and their mean 
age was 37.39±8.39 y. Escitalopram was indicated for either their 
primary problem or additive therapy, as follows: major depressive 
disorder (37%), anxiety disorders (27.78%), schizophrenia 
(18.52%), and additive management (16%). Besides escitalopram, 
34.4% and 31% of the patients were taking other medications for 
depression and anxiety, respectively (table 1). 
  
Table 1: Co-administered medications in our patient cohort 







Most of our patients (71%) had a normal heart rate. However, 
18% of patients taking escitalopram had a relatively fast heart 
rate of>100 beats/min (range: 101-110), indicative of sinus 
tachycardia, whereas 11% of the patients had a slow heart rate 
of<60 beats/min (range: 50-75; table 2). The cohort with 
bradycardia was prescribed only escitalopram. The mean QT of 
patients taking escitalopram was 366.62±28.69 ms, whereas the 
mean QTc was 398.92±16.15 ms. The mean PR interval was 
159.45±25.35 ms, mean QRS was 96.40±9.94 ms, and mean heart 
rate was 80±15.88 beats/min. 
 
Table 2: Dose of escitalopram and heart rate 
Dose Number of patients and categories of heart rate 
<60 bpm 60-100 bpm >100 bpm 
5 mg 0 1 0 
10 mg 4 17 3 
15 mg 0 8 0 
20 mg 2 11 7 




SSRIs are commonly used to treat a range of psychiatric and medical 
disorders, and they are considered effective and relatively safe [19, 
20]. However, some concerns about the cardiotoxicity of SSRIs have 
recently been raised [21]. As escitalopram is one of the most 
commonly used SSRIs, it is essential to confirm whether they are 
associated with cardiac-induced ECG abnormalities [22]. Generally, 
research has shown that escitalopram will reduce one’s heart rate by 
2 beats/min and prolong the QTc by 3.5 ms and that such changes 
are independent of the dose [23]. 
Escitalopram is known to exert similar side effects as citalopram [24, 
25]. However, escitalopram exhibits higher serotonergic toxicity and 
less cardiac toxicity than citalopram [6]. Although escitalopram is 
considered less cardiotoxic than citalopram, several studies have 
demonstrated the effects of escitalopram on the heart, and 
particularly QT prolongation, as this is the most obvious ECG feature 
of patients who have been treated with escitalopram, especially an 
overdose of escitalopram. Most of the reported cases of toxicity 
occurred in patients taking doses that ranged from 20 to 560 mg 
(median = 140 mg) and included varied symptoms, such as 
bradycardia, prolonged QT interval, and serotonin toxicity 
syndrome. Other serious effects were reported when other 
medications were co-ingested along with escitalopram [13]. It is, 
therefore, wise to closely monitor both QRS and QTc in patients who 
have experienced an overdose [26]. There have been no deaths or 
seizures reported from the ingestion of only escitalopram. Following 
at least 6 mo of escitalopram administration, our patients did not 
show any significant increase in either QTc or QRS; both of these 
indices were within the normal range. Evaluating QTc at baseline 
and then again at 6 mo post-therapy may be more useful 
diagnostically. 
Escitalopram has been shown to increase the risk of tachycardia or 
bradycardia in addition to QTc abnormalities [6, 7, 23]. Tachycardia 
may also present in cases of co-ingestion with other medications 
rather than a sole treatment induced by only escitalopram [23]. 
Patients may also develop QT-HR abnormalities, which may be 
considered a risk for torsades de pointes [6, 27]. In our present 
study, 18% and 11% of patients presented with tachycardia and 
bradycardia, respectively, although none of the patients developed 
prolonged QTc that was above the normal range. Therefore, the risk 
of torsade de pointes was minimal or nil. Surprisingly, bradycardia 
developed in only patients who were taking escitalopram alone. 
Hence, further monitoring of such patients is essential. Generally, 
escitalopram is considered a relatively safe choice with minimal ECG 
changes, provided that the dose used remains within the clinical 
ranges. Adding further medications, however, may lead to 
complications. 
There are some limitations to our study that need to be considered. 
First, this study did not report baseline ECG data before the 
initiation of escitalopram. Second, the results may not be 
generalizable because of the nature of metabolic single nucleotide 
polymorphisms in Saudi patients, which may influence the way 
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escitalopram is metabolized. However, recording baselines and 
monitoring ECGs may be judicious. 
CONCLUSION 
Escitalopram seems to be safe in low doses and cause mild clinical 
changes on one’s heart rate. Higher doses should be studied further 
to confirm the Food and Drug Administration warnings regarding 
QTc changes. 
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